The majority of people taking compounded semaglutide or tirzepatide receive it through one of a handful of compounding pharmacies — often bundled into a telehealth program. Understanding who actually makes the medication, and how to evaluate quality, is a step most patients skip. This guide gives you the framework to evaluate compounders the way a careful consumer should.
How the Compounding Supply Chain Works
One of the most important things to understand about the compounded GLP-1 market is that the platform you see advertised and the entity that actually makes your medication are almost always different companies. Most patients don't know this — and it matters for quality evaluation.
Telehealth platforms like Hims & Hers, Ro, Noom, and others are the prescriber and distributor. They employ or contract with licensed medical providers who write prescriptions, manage the patient relationship, handle billing, and handle shipping logistics. The actual compounding — mixing and packaging the medication — is done by a separate pharmacy entity they contract with.
Which pharmacy fulfills your order can vary by state, by which compounders a platform has approved for a given period, and sometimes by supply availability. Patients rarely see this information presented directly, and platforms are not always transparent about it. If you want to know who is making your medication, you have to ask directly — and then you have to know what to do with the answer.
503A vs. 503B: The Regulatory Distinction That Matters
Compounding pharmacies operate under one of two federal regulatory frameworks, and the distinction has significant practical implications for quality:
503A pharmacies are traditional compounding pharmacies that compound medications based on individual patient prescriptions. They are primarily regulated by state pharmacy boards rather than the FDA. They can only compound for specific patients with valid prescriptions, cannot produce large batches speculatively, and face less rigorous federal quality standards. Many excellent local compounding pharmacies operate under 503A. Quality can vary widely because state oversight varies widely.
503B outsourcing facilities are FDA-registered and can produce larger batches of compounded medications. They are subject to current Good Manufacturing Practice (cGMP) standards, periodic FDA inspection, and must register with the FDA. This does not mean they are FDA-approved — compounded medications are never FDA-approved regardless of facility designation — but it does mean a meaningfully higher quality baseline in terms of process controls, sterility testing, and batch documentation.
When you're evaluating any compounding program, knowing whether your medication comes from a 503A or 503B facility is one of the most important pieces of information you can obtain. A 503B facility is not a guarantee of quality, but it raises the floor substantially.
Major Platforms and Their Pharmacy Partners
Below is a description of the major platforms and pharmacies patients commonly encounter. This is not a ranking or endorsement — it is an orientation to who these entities are and what questions to ask about each.
Eden (sometimes referenced as Eden.health in search queries) has become one of the more frequently searched platforms for compounded tirzepatide, particularly around pricing. Eden functions as a telehealth program — it connects patients with prescribers and handles the patient interface — while contracting with compounding pharmacies to fulfill the actual medication orders.
Eden has been cited frequently in searches like "eden compounded tirzepatide pricing 2026," which reflects its competitive positioning on tirzepatide cost relative to some other platforms. However, pricing can change, and availability depends on current regulatory status and which pharmacy partner Eden is working with at a given time.
What to verify: Ask Eden which 503A or 503B pharmacy fulfills your prescription, then independently verify that pharmacy's credentials. Confirm current tirzepatide availability given the evolving regulatory environment. Do not assume pricing from older reviews reflects current offers.
Hims & Hers is one of the largest telehealth platforms in the country and has offered both compounded semaglutide and compounded tirzepatide formulations. Pricing tends to be mid-market relative to other platforms. As a publicly traded company, it operates at significant scale.
In 2025, Hims & Hers had notable regulatory friction around compounded semaglutide, including FDA scrutiny related to labeling and marketing of compounded versions. This is worth understanding when evaluating the platform — it illustrates that even large, well-resourced platforms can run into compliance issues in this regulatory environment, and patient orders can be disrupted when a platform's compounding program changes.
What to verify: Confirm current availability of semaglutide and tirzepatide compounding given the post-2025 regulatory changes. Ask which pharmacy compounds the medication. Review what is included in platform pricing (provider visits, supplies, shipping) to compare accurately with alternatives.
Ro is a telehealth company that operates a weight management program (Ro Body) through which it has offered GLP-1 prescriptions and compounded formulations. Ro uses pharmacy partners for compounding and generally includes provider visit costs in its program pricing structure.
Ro's pricing model tends to bundle services more completely than some competitors — the monthly cost includes ongoing provider access, which is meaningful for patients who want regular clinical contact. Evaluating Ro's effective cost requires looking at what's included versus what you'd pay separately elsewhere.
What to verify: Current availability of compounded options, which pharmacy fulfills orders, and total cost of the program at your likely dose trajectory. Confirm whether the included provider visits are substantive or primarily for prescription renewal.
Henry Meds has positioned itself specifically around GLP-1 prescribing rather than offering a broader telehealth menu. This focus has translated into competitive pricing — particularly on tirzepatide — and providers who are specifically oriented to GLP-1 management. Henry Meds is frequently mentioned in price comparisons for compounded tirzepatide as one of the lower-cost options in the market.
As with other telehealth platforms, Henry Meds contracts with compounding pharmacies to fulfill prescriptions. The specifics of which pharmacy, and that pharmacy's 503A or 503B status, are worth confirming directly.
What to verify: Current tirzepatide and semaglutide availability, pharmacy partner details, whether pricing includes all components you're comparing, and what ongoing clinical support looks like beyond the initial prescription.
Hallandale Health is notable because it is an actual compounding pharmacy — not a telehealth platform layered on top of a pharmacy relationship. Hallandale is well-known within the peptide and compounding communities and has a longer operating history in this space than many newer entrants.
As a direct pharmacy, Hallandale can work with any licensed prescriber who writes a valid prescription. This makes it relevant for patients whose own physicians (primary care, endocrinologist, or obesity medicine specialist) are willing to prescribe and want direct pharmacy relationships rather than telehealth platform middlemen.
What to verify: Current 503A or 503B designation, current availability of specific compounds given regulatory changes to semaglutide compounding, and whether they can ship to your state. Your prescriber will need to have a relationship or be willing to send a script directly.
Many patients work through their own prescriber — a primary care physician, endocrinologist, or obesity medicine specialist — who writes a prescription to a local or regional 503A compounding pharmacy. This path often costs more per unit than the telehealth platforms, but it preserves a direct relationship with a prescriber who knows your full medical history, and the pharmacy relationship is more transparent.
Quality varies significantly across local 503A pharmacies. PCAB accreditation, state pharmacy board status, and willingness to provide Certificates of Analysis are the key vetting points. A good prescriber in this space will typically have relationships with compounders they trust and can make a recommendation.
What to verify: PCAB accreditation, state license in good standing, 503A designation, and whether they can provide CoAs for your batches. Also confirm current legal status of compounding the specific medication you need given the evolving shortage exception rules.
What to Ask Any Compounding Pharmacy
Whether you're evaluating a platform or a direct pharmacy relationship, the same core questions apply. A legitimate, quality-focused compounder will answer all of these without hesitation. Evasiveness is informative.
- Are you a 503A or 503B facility? (503B facilities are FDA-registered and inspected; 503A pharmacies operate under state board oversight. Both can be legitimate — but you should know which you're working with.)
- Can you provide a Certificate of Analysis (CoA) for my batch? (A CoA documents the testing results for potency, sterility, and other parameters for a specific production lot. This is a basic quality document — if a pharmacy won't provide one, that is a red flag.)
- What is the base form of the compound — semaglutide base or semaglutide sodium salt? (FDA-approved Ozempic and Wegovy use semaglutide base. Semaglutide sodium salt is a chemically different compound. The distinction matters for both efficacy and regulatory compliance.)
- What excipients are in the formulation? (Excipients are the non-active ingredients — pH adjusters, preservatives, diluents. You should know what else is in the vial, especially if you have allergies or sensitivities.)
- What are your cold chain shipping procedures? (Temperature-controlled shipping for injectable medications is important for maintaining potency. Ask specifically what they use and how they handle delays.)
- What is your policy if a vial arrives damaged or is suspected to be compromised? (Quality pharmacies have clear remixing or replacement policies. This tells you something about their quality culture.)
→ Related: How to Vet a GLP-1 Telehealth Platform: Red Flags & Fraud Patterns — extends pharmacy due diligence to the full platform: pre-enrollment checklist, billing fraud patterns, cancel safely, and FCBA dispute rights.
Pricing Landscape (What to Expect)
Compounded GLP-1 pricing has shifted considerably over the past year as platforms have competed aggressively and regulatory changes have affected supply. Here is the general range as of mid-2026 — specific current pricing should be verified directly, as this market moves quickly.
The most common comparison mistake is not accounting for what's included. A $199/month platform price that includes provider visits, nursing support, shipping, and supplies may cost less in total than a $149/month pharmacy-only price where you separately pay for telemedicine visits, shipping, and needles. When comparing options, build a complete cost picture for the same dose at the same level of clinical support.
Searches for "Eden compounded tirzepatide pricing 2026" and similar queries have been among the most common on this site — reflecting how much readers are focused on cost. For current data by specific platform and dose tier, see the price comparison page.
Quality Red Flags
The compounded GLP-1 market has attracted some operators with inadequate quality practices. Third-party testing has found potency and sterility issues at a subset of compounders. Knowing what to avoid matters as much as knowing what to look for.
- No Certificate of Analysis available, or the pharmacy refuses to provide one when asked
- Cannot confirm whether they are a 503A or 503B facility — or the designation they claim cannot be verified
- Claims about "enhanced" formulations — added B12, NAD+, peptide blends, or other additives — without clinical evidence that the combination is beneficial or even appropriate
- No licensed prescriber involved in your treatment — any program that allows you to self-prescribe injectable medication is operating improperly
- Pricing that seems implausibly low — quality compounding requires real costs; extreme undercutting often signals corners being cut on quality control, sterility testing, or raw material sourcing
- Inability to answer basic questions about the compound — base vs. salt form, excipient list, lot number — from pharmacy staff
- No clear physical address or state pharmacy license that can be independently verified
The Semaglutide Compounding Situation in 2026
The regulatory situation for compounded semaglutide has changed significantly and is worth understanding clearly, because it affects which options are currently legal and available.
The FDA's authority to permit compounding of a drug that is commercially available relies in part on the drug being in shortage. When Ozempic and Wegovy were in shortage, the FDA allowed compounders to produce copies under the shortage exception. Beginning in late 2024 and continuing into 2025, the FDA ended the shortage designation for branded semaglutide products, concluding that supply had stabilized.
The practical result: compounding pharmacies — particularly 503B outsourcing facilities — that were relying on the shortage exception can no longer legally compound non-personalized semaglutide copies. The FDA has taken enforcement action in this space. Several large compounders exited the semaglutide market or significantly curtailed production.
503A pharmacies have a potentially different legal position. Under federal law, a 503A pharmacy with an individualized patient prescription and a prescriber who has identified a specific clinical need may still be able to compound — this is the "clinical need" exemption rather than the shortage exception. The legal analysis is genuinely complex, and practices vary across states. Some 503A pharmacies are continuing to compound semaglutide on this basis; others have stopped. The legal risk sits primarily with the pharmacy and prescriber, not the patient, but patients should understand what they're participating in.
Tirzepatide: The regulatory analysis for compounded tirzepatide is separate. As of May 2026, many compounders are still operating for tirzepatide based on their assessment of the shortage status and applicable exemptions. This situation may change — follow developments with your prescriber and pharmacy rather than relying on guidance from several months ago.
→ Related: Semaglutide Base vs. Acetate/Sodium Salt: What Compounders Were Actually Making — the chemistry of what different pharmacies sourced, why it mattered legally, and what to ask your compounder.
How to Find a Pharmacy, Not Just a Platform
If you want to go beyond the telehealth platform ecosystem and evaluate compounders more directly, several resources let you do that.
PCAB (Pharmacy Compounding Accreditation Board) is an independent accreditation body that evaluates compounding pharmacies against quality standards. PCAB accreditation is voluntary and not required to operate, but it signals a pharmacy's commitment to quality. You can verify PCAB accreditation on the PCAB website.
FDA 503B Outsourcing Facility List: The FDA maintains a public list of registered 503B outsourcing facilities. If a pharmacy claims 503B status, you can verify it here. This is one of the most useful searches you can do when evaluating a compounder's credentials.
State board of pharmacy: Every state has a pharmacy licensing board, and license status is typically publicly searchable. Verifying that a pharmacy's license is active and in good standing in the state where it operates and ships to you is a basic due diligence step.
Your prescriber: A prescriber who has experience with GLP-1 compounding — an endocrinologist, obesity medicine specialist, or a primary care physician who treats many GLP-1 patients — will typically have working relationships with compounders they have vetted over time. This is underutilized as a resource. If you have access to a quality prescriber, ask them which pharmacies they trust and why.